HDAC9 and neoplasm: HDAC inhibitors substantially enhance INT efficacy through multi-level mechanisms: they activate endogenous retroelements to expand the “antigen repository”, upregulate MHC class I and II expression, strengthen the antigen processing machinery, improve MHC-I complex stability, and favorably remodel the tumor immune microenvironment via modulation of critical chemokine pathways.